The latest Investing Matters Podcast episode featuring Jeremy Skillington, CEO of Poolbeg Pharma has just been released. Listen here.
Happy for you all. Hope its a good day!
I was thinking of buying a tesla but I've just had to settle for a 1996 corsa. Could be worse it's obky rusty on one wing
The way that RNS was written is pretty diabolical. What would a fundraise even by tied to in terms of product pipeline right now. Why would you buy in without a vision from the new CEO. UK gov and odd decisions has thoroughly shafted this business.
Oh look another ex arch ramper who revisits the board pretending they are Warren buffet because they sold a little earlier than others.
"Hope you heeded my advice" what a joke
Bloody hell swag even after all of this you think he's getting a BJ in the car park? Compensation for lost options I guess
The question I was asking myself is why would anyone switch LFT provider now? It's a hugely laborious process to manage within gealthcare systems and you would inevitably get a lot of usability failures as the public adjusted to using a new device.
I see 2 reasons to switch
1) capacity this is still valid but I don't know ow how to measure the potential market for this reason
2) UK government to support UK business. For this one I've just completely lost faith. We are currently suffering from a dangerous combination of corruption and incompetence.
USA is America first, APAC and EEMEA (largely) priced out, Greater China (imagine!) Hahahah, EU why use a British supplier with import red tape.
That is why I lay this scenario at the governments door. I sincerely hope it comes good for the LTH.
Hope it turns around for you swag!
I've reached my limit this morning and sold out at a much lower profit than when the directors sold. I'm getting out of investing for a while as plans afoot to tie up much of my capital for the next few years.
Thanks to all the genuine LTH who I had some good discussions with in the last 2 years.
All the best.
ODX blame the CEO
AVCT blame the CEO
GDR blame the CEO
ABDX blame the CEO
Perhaps it's the landscape the companies are operating in rather than the capabilities of the staff?
UK - massive incompetence and corruption
USA - America first (FDA has always been this way)
EU - why buy from UK after brexit when there's myriad other options
EEMEA and APAC - priced out by UK manufacture and margin costs.
The missed open goal here is UK not purchasing its own tests despite the fact they received EU certification and also were validated by the respected independent body FIND.
Imagine if we had placed billions of pounds if orders in UK diagnostics and these companies were able to reinvest that and grow. I've spent my entire career so far in foreign owned diagnostics companies because they had the investments required to become what they are.
Zzzzzzzz
I remember dreaming of an expanded portfolio too. UK gov got a lot to answer for.
Combination of sky high opinion of yourself and talking absolute garbage are prerequesites of being a tory mp
You strike me as the sort of person who enjoys a good old strangle**** in the closet. What do you gain from blowing your own trumpet every month?
You only have to look ok at the precipitous drop-off of flu incidence when masks were mandated to see how protective the masks are.
I love the experimental shots comments absolute gold dust comments. Nearly everyone I know who is "vaccine hesitant" has regularly sniffed vague white powder cut in a back room and smuggled here in another human backside, smokes more than 20 a day or drinks themselves silly everyday.
A fee micrograms of a highly regulated and tested medical product couldn't possibly hurt in that backdrop could it? Nation of hypocrites
Sounds an awful lot like incompetent political interference in "independent" orgs
The reason this has happened is because the avacta test uses antibodies targeted against the s protein and the majority of omicrons mutations are on the S protein. The mutations reduce the binding affinity of the antibody to the viral protein.
Bline it's months of work required including a new clinical valuation. If this goes beyond 26may or may be subject to the new more stringent regulation too
Thought this could happen since they targeted the S protein. Not good